| Code | CSB-RA015007MB6HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to ABP-692, designed to target MS4A1 (Membrane Spanning 4-Domains A1), also known as CD20. MS4A1 is a cell surface phosphoprotein exclusively expressed on B lymphocytes from the pre-B to mature B-cell stages, playing a crucial role in B-cell development, activation, and calcium influx regulation. This protein serves as an important marker for B-cell lineage and is implicated in various B-cell malignancies including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune disorders such as rheumatoid arthritis and multiple sclerosis.
ABP-692 is a rituximab biosimilar reference antibody that binds specifically to the CD20 antigen on B cells. This biosimilar antibody provides researchers with a valuable tool for investigating B-cell biology, studying mechanisms of B-cell depletion, exploring therapeutic targets in hematological cancers, and examining autoimmune disease pathogenesis. It supports applications in oncology research, immunology studies, and therapeutic antibody development programs.
There are currently no reviews for this product.